Ebselen
- Generic Name
- Ebselen
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H9NOSe
- CAS Number
- 60940-34-3
- Unique Ingredient Identifier
- 40X2P7DPGH
- Background
Ebselen has been investigated for the treatment and basic science of Meniere's Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus.
- Associated Conditions
- -
- Associated Therapies
- -
SPI-1005 in Adults Receiving Cochlear Implant
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Sound Pharmaceuticals, Incorporated
- Target Recruit Count
- 40
- Registration Number
- NCT06340633
IMPase in Treatment-resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 50
- Registration Number
- NCT05117710
- Locations
- 🇬🇧
Neurosciences Building, Dept. Psychiatry, Warneford Hospital, Oxford, Oxfordshire, United Kingdom
SPI-1005 for the Treatment of Meniere's Disease
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Sound Pharmaceuticals, Incorporated
- Target Recruit Count
- 254
- Registration Number
- NCT04677972
- Locations
- 🇺🇸
House Clinic, Los Angeles, California, United States
🇺🇸Sacramento Ear, Nose, & Throat, Roseville, California, United States
🇺🇸ENT and Allergy Associates of Florida, Boca Raton, Florida, United States
SPI-1005 Treatment in Moderate COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sound Pharmaceuticals, Incorporated
- Target Recruit Count
- 60
- Registration Number
- NCT04484025
- Locations
- 🇺🇸
St. Luke's Cystic Fibrosis Center of Idaho, Boise, Idaho, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸Duke University, Durham, North Carolina, United States
SPI-1005 Treatment in Severe COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sound Pharmaceuticals, Incorporated
- Target Recruit Count
- 60
- Registration Number
- NCT04483973
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸St. Luke's Cystic Fibrosis Center of Idaho, Boise, Idaho, United States
🇺🇸Duke University, Durham, North Carolina, United States
Ebselen as an add-on Treatment in Hypo/Mania
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 60
- Registration Number
- NCT03013400
- Locations
- 🇬🇧
Neurosciences Building, Dept. Psychiatry, Warneford Hospital, Oxford, Oxfordshire, United Kingdom
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2008-09-30
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00762671
- Locations
- 🇺🇸
Brigham and Women's Hosptial, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.